Tenax Therapeutics, Inc.

NASDAQ:TENX

Biotechnology

Healthcare
$1.91 +0.88%

+$0.10 today

Market cap
$50.66M
Beta
0.97
P/E (TTM)
-9.4
EPS (TTM)
-$1.28
52W Low $5.34High $18.38

Volume 0.70M

Average 0.62M

TENX Other Non-Cash Items

Other non-cash adjustments that reconcile net income to operating cash flow.

Tenax Therapeutics, Inc.NASDAQ: TENX

Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026

Other non-cash items outflow grows to $0

Q1 FY2026 other non-cash items was $0, compared with $0 a year earlier. Trailing-twelve-month other non-cash items was -$34.71M. Over 3 fiscal years it compounded at +273.8% a year.

Context

  • Other non-cash items increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other non-cash items holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$8.68M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
$19.16M+83217.4% YoY
LTMMar 2026
-$34.71M-3574.7% YoY
Other Non-Cash Items past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+83217.4%——
3-year CAGR+273.8%——
5-year CAGR——
10-year CAGR——

Other Non-Cash Items history

USD · from the cash flow

Latest · FY2025
19.16M USD
Year-over-year change
+83217.4%
4-year CAGR
-3.5%

Other Non-Cash Items vs competitors

How TENX compares with its peers on the latest reported figures

  • TENX's LTM Mar 2026 other non-cash items of $34.71M is the 2nd largest of the 7 companies compared; the peer median is $908K.
  • Its year-over-year change of -3574.7% is the lowest of 6, against a peer median of +225.8%.
  • Over three fiscal years its annual growth of +273.8% compares with a peer median of +16.5%.
TENX Competitors Peer median
Other Non-Cash Items for TENX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$78.47B ———
TENXTenax Therapeutics, Inc.LTM Mar 2026$34.71M -3574.7%+273.8%—
SABSSAB Biotherapeutics, Inc.LTM Jun 2026$15.09M +1088.0%+81.7%—
QTTBQ32 Bio Inc.LTM Mar 2026$4.74M +1213.9%—8.8%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$4.44M -13.4%+12.6%11.9%
BOLDBoundless Bio, Inc.LTM Mar 2026$2.52M +225.8%-31.9%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$708K -73.1%+20.3%—
Peer median (excluding TENX) $908K+225.8%+16.5%10.4%

Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.47M)(11.05M)(7.71M)(17.6M)(52.6M)
Depreciation & Amortization108.98K113.33K8K00
Deferred Income Tax00000
Stock-Based Compensation00191K1.13M0
Change in Working Capital(610.09K)(1.45M)1.58M1.64M(2.36M)
Accounts Receivables(22.5K)0(306K)58K0
Inventory00000
Accounts Payables0(344.95K)1.65M1.06M2.88M
Other Working Capital(587.59K)(1.1M)237K523K(5.25M)
Other Non-Cash Items22.12M366.86K25K23K19.16M
Operating Cash Flow(10.86M)(12.01M)(5.9M)(14.81M)(35.8M)
Capital Expenditures(5.25K)(2.33K)000
Acquisitions (Net)00000
Purchases of Investments(345.54K)0000
Sales of Investments803.4K0000
Other Investing Activities003K00
Investing Cash Flow452.61K(2.32K)3K00
Debt Repayment0624.3K(624K)(501K)0
Common Stock Issued9.19M7.93M14.19M100.37M38.51M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities544.65K0000
Financing Cash Flow9.74M8.55M13.57M99.87M38.51M
Effect of Forex Changes00000
Net Change in Cash(666.32K)(3.46M)7.67M85.06M2.71M
Free Cash Flow(10.86M)(12.02M)(5.9M)(14.81M)(35.8M)

Tenax Therapeutics, Inc.

NASDAQ:TENX

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.